EXELIXIS INC
For the period ended Jan 3, 2025. Filed Feb 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 11, 2025
EXEL$71.74+3.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $217,374 | $262,994 |
| Marketable securities | 893,902 | 732,308 |
| Trade receivables, net | 265,437 | 237,407 |
| Inventory | 22,388 | 17,323 |
| Prepaid expenses and other current assets | 68,478 | 67,926 |
| Total current assets | 1,467,579 | 1,317,958 |
| Non-current marketable securities | 637,291 | 728,717 |
| Property and equipment, net | 119,391 | 128,731 |
| Deferred tax assets, net | 420,027 | 361,145 |
| Goodwill | 63,684 | 63,684 |
| Right-of-use assets and other non-current assets | 239,718 | 342,122 |
| Total assets | $2,947,690 | $2,942,357 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $38,191 | $33,768 |
| Accrued compensation and benefits | 109,830 | 93,325 |
| Accrued clinical trial liabilities | 57,976 | 71,615 |
| Rebates and fees due to customers | 62,376 | 59,619 |
| Accrued collaboration liabilities | 40,384 | 27,533 |
| Other current liabilities | 95,012 | 108,417 |
| Total current liabilities | 403,769 | 394,277 |
| Non-current operating lease liabilities | 190,823 | 189,944 |
| Other non-current liabilities | 108,895 | 94,224 |
| Total liabilities | 703,487 | 678,445 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued | — | — |
| Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 281,732 and 302,793 at December 31, 2024 and 2023, respectively | 282 | 303 |
| Additional paid-in-capital | 2,343,915 | 2,440,710 |
| Accumulated other comprehensive loss | (1,347) | (3,750) |
| Accumulated deficit | (98,647) | (173,351) |
| Total stockholders’ equity | 2,244,203 | 2,263,912 |
| Total liabilities and stockholders’ equity | $2,947,690 | $2,942,357 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.